Evidence map›Paper›PMID 30934019›Full record

ArticlePloS one2019

Interleukin-6 and lipoprotein-associated phospholipase A2 are associated with functional trajectories.

Mandip S Dhamoon, Ying-Kuen Cheung, Yeseon P Moon, Clinton B Wright, Ralph L Sacco, Mitchell S V Elkind

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mandip S DhamoonDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.ORCID 0000-0003-2402-4632
Ying-Kuen CheungDepartment of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, United States of America.
Yeseon P MoonDepartment of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, United States of America.
Clinton B WrightNational Institutes of Health, Bethesda, MD, United States of America.ORCID 0000-0002-9797-6215
Ralph L SaccoMcKnight Brain Institute, Miller School of Medicine, University of Miami, Miami, FL, United States of America.
Mitchell S V ElkindDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States of America.

Funding

Inflammatory and Infectious Burden and Risk of StrokeR01NS048134 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ELKIND, MITCHELL S · 2004 to 2008
$1.5M
The trajectory of functional status and quality of life before and after strokeK23NS079422 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI DHAMOON, MANDIP SINGH · 2013 to 2017
$917k
NINDS NIH HHS K23 NS079422NINDS NIH HHS R01 NS048134
6 · The paper itself

Abstract

BACKGROUND/

objectivesInflammatory biomarkers have been associated with stroke and mortality, but inflammation may also have detrimental effects beyond acute events. We hypothesized that serum concentrations of interleukin-6 (IL6) and lipoprotein-associated phospholipase A2 (LpPLA2) were inversely associated with long-term functional decline independently of vascular risk factors, stroke and myocardial infarction (MI) occurring during follow-up.

designProspective population based cohort study.

settingThe Northern Manhattan Study. PARTICIPANTS (INCLUDING THE SAMPLE SIZE): Race/ethnically diverse stroke-free individuals in northern Manhattan aged ≥40 years (n = 3298).

interventionNone. MEASUREMENTS: Annual functional assessments with the Barthel index (BI), for a median of 13 years. BI was analyzed as a continuous variable (range 0-100). Baseline demographics, risk factors, and laboratory studies were collected, including IL6 (n = 1679), LpPLA2 mass (n = 1912) and activity (n = 1937). Separate mixed models estimated standardized associations between each biomarker and baseline functional status and change over time, adjusting for demographics, vascular risk factors, social variables, cognition, and depression measured at baseline, and stroke and MI occurring during follow-up.

resultsMean age was 69 (SD 10) years, 35% were male, 53% Hispanic, 74% hypertensive, and 16-24% diabetic. LogIL6 was associated with decline in BI over time (-0.13 points per year, 95% CI -0.24, -0.02) and marginally with baseline BI (-0.20, 95% CI -0.40, 0.01). LpPLA2 activity levels were associated with baseline BI (-0.36, 95% CI -0.68, -0.04) but not change over time, and LpPLA2 mass levels were not associated with either.

conclusionIn this large population-based study, higher serum inflammatory biomarker levels were associated with disability, even when adjusting for baseline covariates and stroke and MI occurring during follow-up.

Indexed as

Physical Functional Performance1-Alkyl-2-acetylglycerophosphocholine EsteraseActivities of Daily LivingAdultAgedAged, 80 and overBiomarkersCohort StudiesFemaleHumansInflammation MediatorsInterleukin-6MaleMiddle AgedMyocardial InfarctionNew York City1-Alkyl-2-acetylglycerophosphocholine EsteraseBiomarkersIL6 protein, humanInflammation MediatorsInterleukin-6PLA2G7 protein, human

Identifiers

PMID30934019
PMCPMC6443177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.